Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
1.
Mol Ther ; 21(4): 842-8, 2013 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-23337981

RESUMEN

Vesicular stomatitis virus (VSV) is an oncolytic virus which selectively infects and kills cancer cells. The goal of the present study was to determine whether VSV is capable of targeting metastatic lesions that arise in situ in the transgenic adenocarcinoma of the mouse prostate (TRAMP) model. The interferon (IFN)-responsive luciferase containing VSV(AV3) strain was injected intraprostatically into both control and TRAMP mice. Distribution, infectivity, apoptosis, and status of the IFN response were evaluated at the site of viral injection (prostate), as well as in metastatic lesions (lymph nodes), through plaque, polymerase chain reaction (PCR), and immunohistochemical analysis. Bioluminescence analyses demonstrated that VSV(AV3) persisted at high levels in the prostate region of TRAMP mice for up to 96 hours, but at relatively low levels and for only 48 hours in control mice. Live virus was discovered in the lymph nodes of TRAMP mice, but not in control mice. TUNEL staining revealed increased cell death in VSV(AV3) infected metastatic cells present in the lymph nodes of TRAMP mice. There was an evidence of IFN activation in lymph nodes containing metastatic cells. Our results indicate that intraprostatic injections of VSV(AV3) can be used as a means to infect and kill metastatic lesions associated with advanced prostate cancer.


Asunto(s)
Adenocarcinoma/terapia , Metástasis de la Neoplasia/prevención & control , Viroterapia Oncolítica/métodos , Neoplasias de la Próstata/terapia , Virus de la Estomatitis Vesicular Indiana/fisiología , Animales , Masculino , Ratones , Ratones Transgénicos , Neoplasias de la Próstata/genética , Neoplasias de la Próstata/metabolismo , Virus de la Estomatitis Vesicular Indiana/genética
2.
Comput Biol Med ; 60: 132-42, 2015 May.
Artículo en Inglés | MEDLINE | ID: mdl-25817534

RESUMEN

BACKGROUND: Atrial fibrillation (AF) is the most common cardiac arrhythmia, and a major public health burden associated with significant morbidity and mortality. Automatic detection of AF could substantially help in early diagnosis, management and consequently prevention of the complications associated with chronic AF. In this paper, we propose a novel method for automatic AF detection. METHOD: Stationary wavelet transform and support vector machine have been employed to detect AF episodes. The proposed method eliminates the need for P-peak or R-Peak detection (a pre-processing step required by many existing algorithms), and hence its performance (sensitivity, specificity) does not depend on the performance of beat detection. The proposed method has been compared with those of the existing methods in terms of various measures including performance, transition time (detection delay associated with transitioning from a non-AF to AF episode), and computation time (using MIT-BIH Atrial Fibrillation database). RESULTS: Results of a stratified 2-fold cross-validation reveals that the area under the Receiver Operative Characteristics (ROC) curve of the proposed method is 99.5%. Moreover, the method maintains its high accuracy regardless of the choice of the parameters' values and even for data segments as short as 10s. Using the optimal values of the parameters, the method achieves sensitivity and specificity of 97.0% and 97.1%, respectively. DISCUSSION: The proposed AF detection method has high sensitivity and specificity, and holds several interesting properties which make it a suitable choice for practical applications.


Asunto(s)
Fibrilación Atrial/diagnóstico , Diagnóstico por Computador/métodos , Electrocardiografía , Máquina de Vectores de Soporte , Algoritmos , Arritmias Cardíacas/diagnóstico , Análisis de Fourier , Humanos , Curva ROC , Reproducibilidad de los Resultados , Sensibilidad y Especificidad , Procesamiento de Señales Asistido por Computador , Análisis de Ondículas
3.
Cancer Res ; 70(4): 1367-76, 2010 Feb 15.
Artículo en Inglés | MEDLINE | ID: mdl-20145134

RESUMEN

Vesicular stomatitis virus (VSV) is an oncolytic virus which selectively infects and kills cancer cells. The goal of the present study was to determine the safety and efficacy of VSV treatment of prostate tumors that arise in situ in immunocompetent, transgenic prostate-specific PTEN-null (PTEN(-/-)) mice. Interferon-sensitive VSV(AV3 strain), which expresses luciferase, was injected intraprostatically into tumor-bearing PTEN(-/-) and control mice and then monitored for tissue bioluminescence over 96 hours. Virus readily dispersed throughout the bodies of mice after only 3 hours; however, it persisted at high levels for >72 hours in PTEN(-/-) mice, but at relatively low levels and for only approximately 48 hours in controls. Plaque assays provided a similar pattern, with much higher concentrations of replicating virus in prostates of PTEN(-/-) mice than in controls. Transient, low levels of virus were detected in the spleens of both groups. Apoptotic analyses by terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling staining revealed that VSV(AV3) is able to selectively infect and kill prostate cells in PTEN(-/-) mice, while sparing normal cells in control mice. The primary mechanism for cell kill is apparently apoptotic oncolysis as opposed to neutrophil invasion as has been reported using xenograft models. These results suggest that control of locally advanced human prostate cancer may be achievable through intraprostatic injection and amplification of a safe oncolytic virus, such as VSV(AV3).


Asunto(s)
Carcinoma/terapia , Viroterapia Oncolítica , Fosfohidrolasa PTEN/genética , Neoplasias de la Próstata/terapia , Virus de la Estomatitis Vesicular Indiana/fisiología , Animales , Apoptosis/genética , Carcinoma/genética , Carcinoma/patología , Carcinoma/virología , Supervivencia Celular/genética , Células Cultivadas , Chlorocebus aethiops , Humanos , Masculino , Ratones , Ratones Noqueados , Virus Oncolíticos/fisiología , Fosfohidrolasa PTEN/fisiología , Neoplasias de la Próstata/genética , Neoplasias de la Próstata/patología , Neoplasias de la Próstata/virología , Células Vero , Carga Viral/genética , Carga Viral/fisiología , Ensayos Antitumor por Modelo de Xenoinjerto
4.
Carcinogenesis ; 27(8): 1636-44, 2006 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-16501251

RESUMEN

A wealth of evidence supports the notion that curcumin, a phytochemical present in turmeric, is a potent chemopreventive agent for colon cancer. Its mechanism of action remains incompletely understood. Here we report that curcumin's apoptosis-inducing effects in colon cancer cell lines are accompanied by robust ceramide generation. This occurs through de novo synthesis as the increase in ceramide could be attenuated by pre-incubation of the cells with myriocin, and no changes were observed in sphingomyelin levels, or in either acidic or neutral sphingomyelinase activities. Furthermore, cell death could in part be reversed by myriocin, indicating, for the first time, that endogenous ceramide generation by this agent contributes towards its biological activity. We then investigated the role of reactive oxygen species (ROS) in this phenomenon and demonstrated that curcumin induced robust oxidant generation in the cell lines tested, and its reversal by N-acetylcysteine, completely attenuated apoptosis. We next confirmed that curcumin could activate c-jun N-terminal kinase (JNK) and that its modulation could reverse cell death; however, this intervention could not block ceramide generation, or ROS production. Conversely, however, the inhibition of ROS using N-acetylcysteine led to an inhibition of JNK activation. Hence, we conclude that curcumin induces apoptosis via a ROS-associated mechanism that converges on JNK activation, and to a lesser extent via a parallel ceramide-associated pathway.


Asunto(s)
Antineoplásicos/farmacología , Ceramidas/metabolismo , Neoplasias del Colon , Curcumina/farmacología , Transducción de Señal , Acetilcisteína/farmacología , Apoptosis/efectos de los fármacos , Neoplasias del Colon/tratamiento farmacológico , Neoplasias del Colon/metabolismo , Activación Enzimática/efectos de los fármacos , Ácidos Grasos Monoinsaturados/farmacología , Humanos , Inmunosupresores/farmacología , Proteínas Quinasas JNK Activadas por Mitógenos/antagonistas & inhibidores , Proteínas Quinasas JNK Activadas por Mitógenos/metabolismo , Especies Reactivas de Oxígeno/metabolismo , Células Tumorales Cultivadas/efectos de los fármacos
5.
Am J Physiol Gastrointest Liver Physiol ; 285(5): G919-28, 2003 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-12842827

RESUMEN

Tumor necrosis factor-alpha (TNF-alpha) is a multifunctional cytokine involved in the expression of many genes integral to the inflammatory response. In addition, it activates both apoptotic and survival pathways, the latter being mediated through the activation of the transcription factor nuclear factor-kappaB (NF-kappaB). Protein kinase CK2, a serine-threonine kinase that is universally upregulated in human malignancies, may be involved at multiple levels in this process. However, its role in mediating a survival response within colon cancer cells remains incompletely understood. Here we report that inhibition of CK2 in HCT-116 and HT-29 cells with the use of two specific CK2 inhibitors, 5,6-dichloro-ribifuranosylbenzimidazole (DRB) and apigenin, effected a synergistic reduction in cell survival when used in conjunction with TNF-alpha. Furthermore, there was a demonstrable synergistic reduction in colony formation in soft agar with the use of the same combinations. Western blot analysis showed that poly-ADP ribose polymerase and procaspase-3 cleavage complemented the fluorescence-activated cell sorter analysis findings of significantly increased subdiploid DNA-containing cell populations using these conditions. Remarkably, these events occurred in the absence of any reduction in the expression of the Bcl-2 family members Bcl-2, Mcl-1, and Bcl-xL or any change in the proapoptotic molecules Bad or Bax. One-hybrid NF-kappaB promoter assays utilizing a Gal4-p65 transactivation domain construct revealed that the TNF-induced transactivation was inhibited by both DRB and apigenin. This was associated with a concomitant reduction in the expression of a recognized anti-apoptotic NF-kappaB target, manganese superoxide dismutase, demonstrated by Q-PCR. Our findings indicate a potentially novel strategy for the treatment of colon cancer, one that targets CK2 simultaneous with TNF-alpha administration.


Asunto(s)
Antineoplásicos/farmacología , Apoptosis , Neoplasias del Colon/fisiopatología , Diclororribofuranosil Benzoimidazol/farmacología , Inhibidores Enzimáticos/farmacología , Flavonoides/farmacología , Factor de Necrosis Tumoral alfa/metabolismo , Apigenina , Quinasa de la Caseína II , División Celular/efectos de los fármacos , Línea Celular Tumoral , Supervivencia Celular/efectos de los fármacos , Neoplasias del Colon/patología , Diploidia , Sinergismo Farmacológico , Células HCT116 , Humanos , Quinasa I-kappa B , Proteínas Quinasas Activadas por Mitógenos/metabolismo , FN-kappa B/genética , Proteínas Serina-Treonina Quinasas/antagonistas & inhibidores , Proteínas Serina-Treonina Quinasas/metabolismo , Proteínas Proto-Oncogénicas c-bcl-2/metabolismo , Superóxido Dismutasa/metabolismo , Activación Transcripcional/efectos de los fármacos , Factor de Necrosis Tumoral alfa/farmacología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA